London · Delayed Price · Currency is GBP · Price in USD Viking Therapeutics Statistics
Total Valuation
LON:0VQA has a market cap or net worth of GBP 2.42 billion. The enterprise value is 1.90 billion.
| Market Cap | 2.42B |
| Enterprise Value | 1.90B |
Important Dates
The last earnings date was Wednesday, February 11, 2026.
| Earnings Date | Feb 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 114.79M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +3.33% |
| Shares Change (QoQ) | +1.50% |
| Owned by Insiders (%) | 2.40% |
| Owned by Institutions (%) | 62.55% |
| Float | 110.21M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 5.09 |
| P/TBV Ratio | 5.09 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -7.11 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.33, with a Debt / Equity ratio of 0.00.
| Current Ratio | 9.33 |
| Quick Ratio | 9.21 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7,023.96 |
Financial Efficiency
Return on equity (ROE) is -47.34% and return on invested capital (ROIC) is -32.33%.
| Return on Equity (ROE) | -47.34% |
| Return on Assets (ROA) | -30.27% |
| Return on Invested Capital (ROIC) | -32.33% |
| Return on Capital Employed (ROCE) | -61.55% |
| Weighted Average Cost of Capital (WACC) | 8.12% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -5.24M |
| Employee Count | 51 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -7.73% in the last 52 weeks. The beta is 0.70, so LON:0VQA's price volatility has been lower than the market average.
| Beta (5Y) | 0.70 |
| 52-Week Price Change | -7.73% |
| 50-Day Moving Average | 33.48 |
| 200-Day Moving Average | 31.27 |
| Relative Strength Index (RSI) | 39.52 |
| Average Volume (20 Days) | 15,291 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 8.66 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -292.25M |
| Pretax Income | -267.21M |
| Net Income | -267.21M |
| EBITDA | n/a |
| EBIT | -292.25M |
| Earnings Per Share (EPS) | -2.37 |
Balance Sheet
The company has 524.36 million in cash and 101,791 in debt, with a net cash position of 524.26 million.
| Cash & Cash Equivalents | 524.36M |
| Total Debt | 101,791 |
| Net Cash | 524.26M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 474.82M |
| Book Value Per Share | 4.14 |
| Working Capital | 474.73M |
Cash Flow
| Operating Cash Flow | -207.06M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LON:0VQA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.33% |
| Shareholder Yield | -3.33% |
| Earnings Yield | -11.05% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |